SR One

VC Redwood City, United States · Founded 1985

SR One is a transatlantic biotechnology venture capital firm that partners with founders and entrepreneurs to translate innovative science into next-generation medicines. The firm employs a hands-on, back-and-build investment strategy focusing on companies with strong underlying fundamentals, clearly defined development pathways, and novel approaches to addressing diseases.

About SR One

SR One is a long-established healthcare-focused venture firm with deep roots in life sciences, originally as the corporate venture arm of GlaxoSmithKline and now operating as an independent fund with continued GSK alignment. The firm focuses on therapeutics across discovery, preclinical, and clinical stages, with a portfolio that has produced multiple FDA-approved drugs and significant commercial outcomes. Check sizes are large by venture standards, typically beginning in the low single-digit millions at initial commitment and extending to fifteen to thirty million dollars or more in cumulative investment over the life of a company through follow-ons. The natural fit is a therapeutics company with credible scientific founders, a clear development pathway, and the ambition to advance assets through clinical milestones. AI-native drug discovery platforms can engage if the platform is anchored by specific assets, partnerships, or a clear translational thesis; software-only theses without a therapeutic asset will not match. Digital health, medical devices, and provider-side enterprise software are out of scope. Founders should expect rigorous, multi-month scientific diligence with input from internal scientific staff and external advisors, and a partner-track relationship that includes board engagement and active development guidance. The best entry path is a warm introduction from a portfolio CEO, a biotech banker, an academic advisor with SR One relationships, or a scientific founder in the firm’s network. Direct outreach via LinkedIn is acceptable when accompanied by a substantive scientific package.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Team

Simeon J. George, MD
Founder & CEO
LinkedIn
Rajeev Dadoo, PhD
COO & Managing Partner
LinkedIn
Jake Nunn
Partner
LinkedIn
Philip Habib
Head of Capital Partnering
LinkedIn
Sasha Keough
General Counsel & Chief Compliance Officer
LinkedIn
James Macadam
Chief Financial Officer
LinkedIn

Pitch / review this investor

Have you raised from SR One? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.